Evidence map›Paper›PMID 38532575›Full record

ArticleBritish journal of haematology2024

Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project.

Monica Civallero, Joseph G Schroers-Martin, Steven Horwitz, Martina Manni, Yana Stepanishyna, Maria Elena Cabrera, Julie Vose, Michele Spina, Felicitas Hitz, Arnon Nagler and 14 more

Registry-linked trialOpen access · greenAbstract readMulticenter Study
In one paragraph

Article in British journal of haematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06468267 (Reduced Intensity Conditioning With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine in Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma.), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06468267 phase2unknown statusnot on this map

Reduced Intensity Conditioning With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine in Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma.

TypeinterventionalSponsorXianmin Song, MDRan2024 to 2026Enrolled50ConditionsPeripheral T Cell LymphomaArmsThiotepa
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 19 institutions in 10 countries.

Monica CivalleroCHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy.
Joseph G Schroers-MartinDivision of Oncology, Department of Medicine, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0003-4128-2537
Steven HorwitzDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.ORCID https://orcid.org/0000-0002-6399-2006
Martina ManniDepartment of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
Yana StepanishynaDepartment of Bone Marrow Transplant, National Cancer Institute, Kyiv, Ukraine.ORCID https://orcid.org/0000-0002-7884-193X
Maria Elena CabreraSección Hematología, Hospital del Salvador, Universidad de Chile, Santiago, Chile.
Julie VoseDivision of Hematology/Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Michele SpinaDivision of Medical Oncology and Immune-Related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
Felicitas HitzDepartment of Oncology/Haematology, The Swiss Group for Clinical Cancer Research, Cantonal Hospital, St Gallen, Switzerland.
Arnon NaglerDepartment of Bone Marrow Transplantation, Tel-Aviv University, Tel-Aviv, Israel.ORCID https://orcid.org/0000-0002-0763-1265
Silvia MontotoDepartment of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Carlos ChiattoneHigienopolis and Santa Casa Medical School of Sao Paulo, Samaritano Hospital, São Paulo, Brazil.
Tetiana SkrypetsHematology and Cell Therapy Department, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy.
M Angeles Perez SaenzDepartment of Hematology, Health Research Institute IIS-FJD, Fundacion Jimenez Diaz University Hospital, Madrid, Spain.
Giorgio PrioloHematology 2, San Giovanni Battista Hospital and University, Turin, Italy.
Stefano LuminariHematology Unit, Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy.ORCID https://orcid.org/0000-0001-8446-2285
Athina LymboussakiCHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy.
Astrid PavlovskyFundación para Combatir la Leucemia (FUNDALEU), Centro de Hematología Pavlovsky, Buenos Aires, Argentina.ORCID https://orcid.org/0000-0002-2068-3721
Dario MarinoDepartment of Oncology, Oncology 1 Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Marina LiberatiA.O. Santa Maria, S.C. di Oncoematologia di Terni, Università Degli Studi di Perugia, Perugia, Italy.ORCID https://orcid.org/0000-0002-3686-3188
Judith TrotmanConcord Repatriation General Hospital, University of Sydney, Concord, New South Wales, Australia.ORCID https://orcid.org/0000-0001-8009-4593
Donato ManninaHematology Unit, AO Papardo, Messina, Italy.
Massimo FedericoCHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy.
Ranjana AdvaniDivision of Oncology, Department of Medicine, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0002-3219-2292
University of Modena and Reggio Emilia · ITStanford Medicine · USAzienda Ospedaliera Ospedali Riuniti Papardo Piemonte · ITAzienda Ospedaliero Universitaria San Giovanni Battista · ITAzienda Sanitaria Unità Locale di Reggio Emilia · ITCentro di Riferimento Oncologico · ITHospital del Salvador · CLHospital Samaritano de São Paulo · BRHospital Universitario Fundación Jiménez Díaz · ESIstituto Oncologico Veneto · ITIstituto Tumori Bari · ITMemorial Sloan Kettering Cancer Center · USNational Cancer Institute · UASt Bartholomew's Hospital · GBSwiss Group For Clinical Cancer Research · CHTel Aviv University · ILThe University of Sydney · AUUniversity of Nebraska Medical Center · USUniversity of Perugia · IT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Associazione Angela Serra per la Ricerca sul CancroFondazione Cassa di Risparmio di ModenaFondazione Italiana LinfomiNCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable disease control, and little is known regarding long-term outcomes. The International T-cell Lymphoma Project (ITCLP) is the largest prospectively collected cohort of patients with PTCLs, providing insight into clinical outcomes at academic medical centres globally. We performed a long-term outcome analysis on patients from the ITCLP with available 10-year follow-up data (n = 735). The overall response rate to first-line therapy was 68%, while 5- and 10-year overall survival estimates were 49% and 40% respectively. Most deaths occurred prior to 5 years, and for patients alive at 5 years, the chance of surviving to 10 years was 84%. However, lymphoma remained the leading cause of death in the 5- to 10-year period (67%). Low-risk International Prognostic Index and Prognostic Index for T-cell lymphoma scores both identified patients with improved survival, while in multivariate analysis, age >60 years and Eastern Cooperative Oncology Group performance status 2-4 were associated with inferior outcomes. The favourable survival seen in patients achieving durable initial disease control emphasizes the unmet need for optimal front-line therapeutic approaches in PTCLs.

Indexed as

Lymphoma, T-Cell, PeripheralAdolescentAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisProspective StudiesTreatment OutcomeYoung Adultfollow‐upoutcomeT‐cell lymphomasTCP1

Identifiers

PMID38532575
PMCPMC11931637
OpenAlexW4393231722

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.